Roche Palo Alto LLC

Hoffmann-la Roche Inc.

Other

Coval Biopharma (shanghai) Co., Ltd.

F. Hoffmann-la Roche Ag

Lichun Feng

Li Chen

Michael Patrick Dillon

Minmin Yang

Ronald Charles Hawley

Mengwei Huang

Yongfu Liu

Guolong Wu

Hongying Yun

Mingwei Zhou

Jim Zhen Wu

Tao Guo

Yun He

Lisha Wang

Chungen Liang

Xiufang Zheng

Song Feng

Lu Gao

Xihan Wu

Jason Christopher Wong

Yingjie Lai

Jefferson Wright Tilley

Sung-Sau So

Jia Tao Li

Robert Francis Kester

Nancy-Ellen Haynes

Fajun Nan

Wendy Lea Corbett

Steven Joseph Berthel

Shixiang Yan

Hao Zhang

Yongguo Li

Mei Zhang

Dafeng Li

Weijiang Zhang

Tao Pang

Lifang Yu

An anti-inflammatory drug compound, and a preparation method therefor and the use thereof. The structural formula of the compound is A-Y—B, wherein A is a group after dehydrogenation of an amine compound having JAK inhibitory activity, Y is a direct connection or —(CH2)-O— or, and B is a group formed by means of dehydroxylation of a carboxy-containing carboxylic acid compound B1, or a group formed by means of dehydrogenation of a hydroxy-containing compound B2. The compound has the special effects of having a strong transdermal property, controlled drug release, high efficacy, etc.

Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof

A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein Rto R, A, Q, X and Y are as defined in the specification and claims, and their use as a pharmaceutical for the treatment or prophylaxis of respiratory syncytial virus disease.

Compounds for the treatment and prophylaxis of respiratory syncytial virus disease

A method of antagonizing P2Xand/or P2Xreceptors or treating a disease misregulation of P2Xand/or P2Xreceptors treating a patient with a compound of formula I wherein R, R, R, R, Rand Rare as defined herein, or a pharmaceutically acceptable salt thereof. wherein, Ris optionally substituted tetrazolyl, Ris optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R, R, Rand Rare as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2Xand/or a P2Xreceptor antagonist and methods of making the compounds.

[object Object]

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris optionally substituted pyrazolyl, and R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2Xand/or a P2Xreceptor antagonists and methods of making the compounds.

A method for treating diseases mediated by a P2Xand/or a P2Xreceptor with compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris an optionally substituted thiazole, oxazole, isothiazole or isoxazole and X, R, R, R, R, R, Rand Rare as defined herein.

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris a group of formula A or formula B, and X, R, R, R, R, R, Rand Rare as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2Xand/or a P2Xreceptor antagonist and methods of making the subject compounds.

Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, X, Y, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2Xand/or a P2Xreceptor antagonists and methods of making the compounds.

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris optionally substituted tetrazolyl, Ris optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R, R, R, RRand Rare as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2Xand/or a P2Xreceptor antagonist and methods of making the compounds.

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris optionally substituted thiadiazolyl, and R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2Xand/or a P2Xreceptor antagonists and methods of making the compounds.

Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris optionally substituted tetrazolyl, Ris optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R, R, Rand Rare as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2Xand/or a P2Xreceptor antagonist and methods of making the compounds.

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein Rto R, Ato Ahave the are as described herein and compositions including the compounds.

Tetrahydroquinoline derivatives

The present invention provides compounds of formula (I), as well as pharmaceutically acceptable salt thereof, wherein Rto Rhave the significance given herein. The compounds are useful in the treatment of prophylaxis of diseases that are related to AMPK regulation.

Alkene oxindole derivatives

Growing community of inventors

Shanghai, China

Lichun Feng